<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38927430</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 Spike Protein 1 Causes Aggregation of &#x3b1;-Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS: Potential Therapeutic Applications of Metformin.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1223</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12061223</ELocationID><Abstract><AbstractText>Abnormal aggregation of &#x3b1;-synuclein is the hallmark of neurodegenerative diseases, classified as &#x3b1;-synucleinopathies, primarily occurring sporadically. Their onset is associated with an interaction between genetic susceptibility and environmental factors such as neurotoxins, oxidative stress, inflammation, and viral infections. Recently, evidence has suggested an association between neurological complications in long COVID (sometimes referred to as 'post-acute sequelae of COVID-19') and &#x3b1;-synucleinopathies, but its underlying mechanisms are not completely understood. In this study, we first showed that SARS-CoV-2 Spike protein 1 (S1) induces &#x3b1;-synuclein aggregation associated with activation of microglial cells in the rodent model. In vitro, we demonstrated that S1 increases aggregation of &#x3b1;-synuclein in BE(2)M-17 dopaminergic neurons via BV-2 microglia-mediated inflammatory responses. We also identified that S1 directly affects aggregation of &#x3b1;-synuclein in dopaminergic neurons through increasing mitochondrial ROS, though only under conditions of sufficient &#x3b1;-Syn accumulation. In addition, we observed a synergistic effect between S1 and the neurotoxin MPP+ S1 treatment. Combined with a low dose of MPP+, it boosted &#x3b1;-synuclein aggregation and mitochondrial ROS production compared to S1 or the MPP+ treatment group. Furthermore, we evaluated the therapeutic effects of metformin. The treatment of metformin suppressed the S1-induced inflammatory response and &#x3b1;-synucleinopathy. Our findings demonstrate that S1 promotes &#x3b1;-synucleinopathy via both microglia-mediated inflammation and mitochondrial ROS, and they provide pathological insights, as well as a foundation for the clinical management of &#x3b1;-synucleinopathies and the onset of neurological symptoms after the COVID-19 outbreak.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Moon Han</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Division of Brain Diseases Research, Department of Chronic Disease Convergence Research, Korea National Institute of Health, 187 Osongsaengmyeong2(i)-ro, Osong-eup, Heungdeok-gu, Cheongju-si 28159, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jung Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Brain Diseases Research, Department of Chronic Disease Convergence Research, Korea National Institute of Health, 187 Osongsaengmyeong2(i)-ro, Osong-eup, Heungdeok-gu, Cheongju-si 28159, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hye Kyung</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Division of Brain Diseases Research, Department of Chronic Disease Convergence Research, Korea National Institute of Health, 187 Osongsaengmyeong2(i)-ro, Osong-eup, Heungdeok-gu, Cheongju-si 28159, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ji Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Brain Diseases Research, Department of Chronic Disease Convergence Research, Korea National Institute of Health, 187 Osongsaengmyeong2(i)-ro, Osong-eup, Heungdeok-gu, Cheongju-si 28159, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Young Ho</ForeName><Initials>YH</Initials><Identifier Source="ORCID">0000-0001-9934-5321</Identifier><AffiliationInfo><Affiliation>Division of Brain Diseases Research, Department of Chronic Disease Convergence Research, Korea National Institute of Health, 187 Osongsaengmyeong2(i)-ro, Osong-eup, Heungdeok-gu, Cheongju-si 28159, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021-NI-020-02</GrantID><Agency>Research of Korea Centers for Disease Control and Prevention</Agency><Country/></Grant><Grant><GrantID>2020-NI-024-02</GrantID><Agency>Research of Korea Centers for Disease Control and Prevention</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 Spike protein 1</Keyword><Keyword MajorTopicYN="N">dopaminergic neuron</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">metformin</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">mitochondrial ROS</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">neurotoxin MPP+</Keyword><Keyword MajorTopicYN="N">&#x3b1;-synucleinopathy</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38927430</ArticleId><ArticleId IdType="pmc">PMC11200543</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12061223</ArticleId><ArticleId IdType="pii">biomedicines12061223</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alafuzoff I., Hartikainen P.  Chapter 24&#x2014;Alpha-synucleinopathies. In: Kovacs G.G., Alafuzoff I., editors. Handbook of Clinical Neurology. Elsevier; Amsterdam, The Netherlands: 2018.  [(accessed on 14 December 2023)]. pp. 339&#x2013;353. Available online:  https://www.sciencedirect.com/science/article/pii/B9780128023952000249.</Citation><ArticleIdList><ArticleId IdType="pubmed">28987181</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann H., Stevens C.H., Cartwright H., Halliday G.M. &#x3b1;-Synucleinopathy phenotypes. Park. Relat. Disord. 2014;20:S62&#x2013;S67. doi: 10.1016/S1353-8020(13)70017-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(13)70017-8</ArticleId><ArticleId IdType="pubmed">24262191</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L. &#x3b1;-Synuclein in Parkinson&#x2019;s Disease. Cold Spring Harb. Perspect. Med. 2012;2:a009399. doi: 10.1101/cshperspect.a009399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a009399</ArticleId><ArticleId IdType="pmc">PMC3281589</ArticleId><ArticleId IdType="pubmed">22355802</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner S.B. Neurodegenerative Diseases and Prions. N. Engl. J. Med. 2001;344:1516&#x2013;1526. doi: 10.1056/NEJM200105173442006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105173442006</ArticleId><ArticleId IdType="pubmed">11357156</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleidi M., Gasser T. The role of inflammation in sporadic and familial Parkinson&#x2019;s disease. Cell. Mol. Life Sci. 2013;70:4259&#x2013;4273. doi: 10.1007/s00018-013-1352-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1352-y</ArticleId><ArticleId IdType="pmc">PMC11113951</ArticleId><ArticleId IdType="pubmed">23665870</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlajinac H., Dzoljic E., Maksimovic J., Marinkovic J., Sipetic S., Kostic V. Infections as a risk factor for Parkinson&#x2019;s disease: A case&#x2013;control study. Int. J. Neurosci. 2013;123:329&#x2013;332. doi: 10.3109/00207454.2012.760560.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2012.760560</ArticleId><ArticleId IdType="pubmed">23270425</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris M.A., Tsui J.K., Marion S.A., Shen H., Teschke K. Association of Parkinson&#x2019;s disease with infections and occupational exposure to possible vectors.  [(accessed on 14 December 2023)];Mov. Disord. 2012 27:1111&#x2013;1117. doi: 10.1002/mds.25077. Available online:  https://movementdisorders.onlinelibrary.wiley.com/doi/abs/10.1002/mds.25077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25077</ArticleId><ArticleId IdType="doi">10.1002/mds.25077</ArticleId><ArticleId IdType="pubmed">22753266</ArticleId></ArticleIdList></Reference><Reference><Citation>Mccall S., Henry J.M., Reid A.H., Taubenberger J.K. Influenza RNA not Detected in Archival Brain Tissues from Acute Encephalitis Lethargica Cases or in Postencephalitic Parkinson Cases. J. Neuropathol. Exp. Neurol. 2001;60:696&#x2013;704. doi: 10.1093/jnen/60.7.696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/60.7.696</ArticleId><ArticleId IdType="pubmed">11444798</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Z.-M., Chertow D.S., Ambroggio X., McCall S., Przygodzki R.M., Cunningham R.E., Maximova O.A., Kash J.C., Morens D.M., Taubenberger J.K. Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc. Natl. Acad. Sci. USA. 2011;108:16416&#x2013;16421. doi: 10.1073/pnas.1111179108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1111179108</ArticleId><ArticleId IdType="pmc">PMC3182717</ArticleId><ArticleId IdType="pubmed">21930918</ArticleId></ArticleIdList></Reference><Reference><Citation>Marreiros R., M&#xfc;ller-Schiffmann A., Trossbach S.V., Prikulis I., H&#xe4;nsch S., Weidtkamp-Peters S., Moreira A.R., Sahu S., Soloviev I., Selvarajah S., et al. Disruption of cellular proteostasis by H1N1 influenza A virus causes &#x3b1;-synuclein aggregation. Proc. Natl. Acad. Sci. USA. 2020;117:6741&#x2013;6751. doi: 10.1073/pnas.1906466117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1906466117</ArticleId><ArticleId IdType="pmc">PMC7104400</ArticleId><ArticleId IdType="pubmed">32152117</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H., Boltz D., Sturm-Ramirez K., Shepherd K.R., Jiao Y., Webster R., Smeyne R.J. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl. Acad. Sci. USA. 2009;106:14063&#x2013;14068. doi: 10.1073/pnas.0900096106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900096106</ArticleId><ArticleId IdType="pmc">PMC2729020</ArticleId><ArticleId IdType="pubmed">19667183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105924</ArticleId><ArticleId IdType="pmc">PMC7127800</ArticleId><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C. Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome? Mol. Neurobiol. 2022;59:1850&#x2013;1861. doi: 10.1007/s12035-021-02696-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02696-0</ArticleId><ArticleId IdType="pmc">PMC8757925</ArticleId><ArticleId IdType="pubmed">35028901</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalash A., Helmy A., Salama M., Gaber A., El-Belkimy M., Hamid E. A 6-month longitudinal study on worsening of Parkinson&#x2019;s disease during the COVID-19 pandemic. Npj Park. Dis. 2022;8:111. doi: 10.1038/s41531-022-00376-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-022-00376-x</ArticleId><ArticleId IdType="pmc">PMC9428872</ArticleId><ArticleId IdType="pubmed">36045133</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E., Xie Y., Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat. Med. 2022;28:2406&#x2013;2415. doi: 10.1038/s41591-022-02001-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02001-z</ArticleId><ArticleId IdType="pmc">PMC9671811</ArticleId><ArticleId IdType="pubmed">36138154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearon C., Fasano A. Parkinson&#x2019;s Disease and the COVID-19 Pandemic. J. Park. Dis. 2021;11:431&#x2013;444. doi: 10.3233/JPD-202320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-202320</ArticleId><ArticleId IdType="pmc">PMC8150477</ArticleId><ArticleId IdType="pubmed">33492244</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao A.R., Hidayathullah S.M., Hegde K., Adhikari P. Parkinsonism: An emerging post COVID sequelae. IDCases. 2022;27:e01388. doi: 10.1016/j.idcr.2022.e01388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2022.e01388</ArticleId><ArticleId IdType="pmc">PMC8733235</ArticleId><ArticleId IdType="pubmed">35018281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Shen J., Jiang Y., Shen X., Wang P., Nie X., Kang W., Liu J., Chen W. Clinical characteristics and outcome of COVID-19 patients with Parkinson&#x2019;s disease: A hospital-based case&#x2013;control study in Shanghai, China. Front. Aging Neurosci. 2023;15:1138418. doi: 10.3389/fnagi.2023.1138418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2023.1138418</ArticleId><ArticleId IdType="pmc">PMC10196628</ArticleId><ArticleId IdType="pubmed">37213541</ArticleId></ArticleIdList></Reference><Reference><Citation>VanElzakker M.B., Bues H.F., Brusaferri L., Kim M., Saadi D., Ratai E.-M., Dougherty D.D., Loggia M.L. Neuroinflammation in post-acute sequelae of COVID-19 (PASC) as assessed by [11C]PBR28 PET correlates with vascular disease measures. bioRxiv. 2023 doi: 10.1101/2023.10.19.563117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.10.19.563117</ArticleId><ArticleId IdType="pmc">PMC11225883</ArticleId><ArticleId IdType="pubmed">38642615</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Francisco E.B., Yogendra R., Long E., Pise A., Rodrigues H., Hall E., Herrera M., Parikh P., Guevara-Coto J., et al. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front. Immunol. 2022;12:746021. doi: 10.3389/fimmu.2021.746021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V., Mahajan A., Krishnamachary B., Spikes L., Chalise P., Dhillon N.K. Persistent Presence of Spike protein and Viral RNA in the Circulation of Individuals with Post-Acute Sequelae of COVID-19. medRxiv. 2022 doi: 10.1101/2022.08.07.22278520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.07.22278520</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong Z., Mai H., Kapoor S., Puelles V.G., Czogalla J., Sch&#xe4;dler J., Vering J., Delbridge C., Steinke H., Frenzel H., et al. SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19. bioRxiv. 2023 doi: 10.1101/2023.04.04.535604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.04.535604</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontes-Dantas F.L., Fernandes G.G., Gutman E.G., De Lima E.V., Antonio L.S., Hammerle M.B., Mota-Araujo H.P., Colodeti L.C., Ara&#xfa;jo S.M.B., Froz G.M., et al. SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. Cell Rep. 2023;42:112189. doi: 10.1016/j.celrep.2023.112189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112189</ArticleId><ArticleId IdType="pmc">PMC9935273</ArticleId><ArticleId IdType="pubmed">36857178</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J., Cho W.-H., Barcelon E., Kim K.H., Hong J., Lee S.J. SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death. Sci. Rep. 2022;12:5496. doi: 10.1038/s41598-022-09410-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-09410-7</ArticleId><ArticleId IdType="pmc">PMC8970073</ArticleId><ArticleId IdType="pubmed">35361832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon H.S., Koh S.-H. Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes. Transl. Neurodegener. 2020;9:42. doi: 10.1186/s40035-020-00221-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00221-2</ArticleId><ArticleId IdType="pmc">PMC7689983</ArticleId><ArticleId IdType="pubmed">33239064</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen Reish H.E., Standaert D.G. Role of &#x3b1;-synuclein in inducing innate and adaptive immunity in Parkinson disease. J. Park. Dis. 2015;5:1&#x2013;19. doi: 10.3233/JPD-140491.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-140491</ArticleId><ArticleId IdType="pmc">PMC4405142</ArticleId><ArticleId IdType="pubmed">25588354</ArticleId></ArticleIdList></Reference><Reference><Citation>Faustini G., Bono F., Valerio A., Pizzi M., Spano P., Bellucci A. Mitochondria and &#x3b1;-Synuclein: Friends or Foes in the Pathogenesis of Parkinson&#x2019;s Disease? Genes. 2017;8:377. doi: 10.3390/genes8120377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes8120377</ArticleId><ArticleId IdType="pmc">PMC5748695</ArticleId><ArticleId IdType="pubmed">29292725</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh T.V., Rethi L., Lee T.-W., Higa S., Kao Y.-H., Chen Y.-J. Spike Protein Impairs Mitochondrial Function in Human Cardiomyocytes: Mechanisms Underlying Cardiac Injury in COVID-19. Cells. 2023;12:877. doi: 10.3390/cells12060877.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12060877</ArticleId><ArticleId IdType="pmc">PMC10046940</ArticleId><ArticleId IdType="pubmed">36980218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X., Nguyen V., Tsai J., Gao C., Tian Y., Zhang Y., Carver W., Kiaris H., Cui T., Tan W. The SARS-CoV-2 spike protein induces long-term transcriptional perturbations of mitochondrial metabolic genes, causes cardiac fibrosis, and reduces myocardial contractile in obese mice. Mol. Metab. 2023;74:101756. doi: 10.1016/j.molmet.2023.101756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2023.101756</ArticleId><ArticleId IdType="pmc">PMC10281040</ArticleId><ArticleId IdType="pubmed">37348737</ArticleId></ArticleIdList></Reference><Reference><Citation>Clough E., Inigo J., Chandra D., Chaves L., Reynolds J.L., Aalinkeel R., Schwartz S.A., Khmaladze A., Mahajan S.D. Mitochondrial Dynamics in SARS-CoV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID. J. Neuroimmune Pharmacol. 2021;16:770&#x2013;784. doi: 10.1007/s11481-021-10015-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-021-10015-6</ArticleId><ArticleId IdType="pmc">PMC8487226</ArticleId><ArticleId IdType="pubmed">34599743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Dai L., Deng M., Xiao T., Zhang Z., Zhang Z. SARS-CoV-2 Spike Protein S1 Domain Accelerates &#x3b1;-Synuclein Phosphorylation and Aggregation in Cellular Models of Synucleinopathy. Mol. Neurobiol. 2023;61:2446&#x2013;2458. doi: 10.1007/s12035-023-03726-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-023-03726-9</ArticleId><ArticleId IdType="pubmed">37897633</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Zhang X., Huang Z., Ma K. SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro. Int. J. Mol. Sci. 2022;23:3394. doi: 10.3390/ijms23063394.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23063394</ArticleId><ArticleId IdType="pmc">PMC8949667</ArticleId><ArticleId IdType="pubmed">35328814</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernicova M. Korbonits Metformin-mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 2014;10:143&#x2013;156. doi: 10.1038/nrendo.2013.256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2013.256</ArticleId><ArticleId IdType="pubmed">24393785</ArticleId></ArticleIdList></Reference><Reference><Citation>Xenos D., Mecocci P., Boccardi V. A blast from the past: To tame time with metformin. Mech. Ageing Dev. 2022;208:111743. doi: 10.1016/j.mad.2022.111743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2022.111743</ArticleId><ArticleId IdType="pubmed">36279989</ArticleId></ArticleIdList></Reference><Reference><Citation>Katila N., Bhurtel S., Shadfar S., Srivastav S., Neupane S., Ojha U., Jeong G.-S., Choi D.-Y. Metformin lowers &#x3b1;-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson&#x2019;s disease. Neuropharmacology. 2017;125:396&#x2013;407. doi: 10.1016/j.neuropharm.2017.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2017.08.015</ArticleId><ArticleId IdType="pubmed">28807678</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;abuzek K., Suchy D., Gabryel B., Bielecka A., Liber S., Okopie&#x144; B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol. Rep. 2010;62:956&#x2013;965. doi: 10.1016/S1734-1140(10)70357-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1734-1140(10)70357-1</ArticleId><ArticleId IdType="pubmed">21098880</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T., Yu J., Zhu X., Wang H., Tan M., Cao L., Zhang Q., Gao L., Shi J., Zhang Y., et al. Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. Br. J. Pharmacol. 2014;171:3146&#x2013;3157. doi: 10.1111/bph.12655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12655</ArticleId><ArticleId IdType="pmc">PMC4080970</ArticleId><ArticleId IdType="pubmed">24611741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng T.P., Feng L., Yap K.B., Lee T.S., Tan C.H., Winblad B. Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes. J. Alzheimer&#x2019;s Dis. 2014;41:61&#x2013;68. doi: 10.3233/JAD-131901.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-131901</ArticleId><ArticleId IdType="pubmed">24577463</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil S.P., Jain P.D., Ghumatkar P.J., Tambe R., Sathaye S. Neuroprotective effect of metformin in MPTP-induced Parkinson&#x2019;s disease in mice. Neuroscience. 2014;277:747&#x2013;754. doi: 10.1016/j.neuroscience.2014.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2014.07.046</ArticleId><ArticleId IdType="pubmed">25108167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlqvist M.L., Lee M.-S., Hsu C.-C., Chuang S.-Y., Lee J.-T., Tsai H.-N. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson&#x2019;s disease occurring with Type 2 diabetes in a Taiwanese population cohort. Park. Relat. Disord. 2012;18:753&#x2013;758. doi: 10.1016/j.parkreldis.2012.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2012.03.010</ArticleId><ArticleId IdType="pubmed">22498320</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M., Su C., Qiao C., Bian Y., Ding J., Hu G. Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson&#x2019;s Disease via Autophagy and Mitochondrial ROS Clearance. Int. J. Neuropsychopharmacol. 2016;19:pyw047. doi: 10.1093/ijnp/pyw047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyw047</ArticleId><ArticleId IdType="pmc">PMC5043649</ArticleId><ArticleId IdType="pubmed">27207919</ArticleId></ArticleIdList></Reference><Reference><Citation>Orihuela R., McPherson C.A., Harry G.J. Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol. 2016;173:649&#x2013;665. doi: 10.1111/bph.13139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13139</ArticleId><ArticleId IdType="pmc">PMC4742299</ArticleId><ArticleId IdType="pubmed">25800044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T.-K., Bae E.-J., Jung B.C., Choi M., Shin S.J., Park S.J., Kim J.T., Jung M.K., Ulusoy A., Song M.-Y., et al. Inflammation promotes synucleinopathy propagation. Exp. Mol. Med. 2022;54:2148&#x2013;2161. doi: 10.1038/s12276-022-00895-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00895-w</ArticleId><ArticleId IdType="pmc">PMC9794777</ArticleId><ArticleId IdType="pubmed">36473937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S., Chun Y., Lee J.S., Lee S.-J. Neuroinflammation in Synucleinopathies. Brain Pathol. 2016;26:404. doi: 10.1111/bpa.12371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12371</ArticleId><ArticleId IdType="pmc">PMC8028946</ArticleId><ArticleId IdType="pubmed">26940152</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato H., Kato T., Arawaka S. The role of Ser129 phosphorylation of &#x3b1;-synuclein in neurodegeneration of Parkinson&#x2019;s disease: A review of in vivo models. Rev. Neurosci. 2013;24:115&#x2013;123. doi: 10.1515/revneuro-2012-0071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2012-0071</ArticleId><ArticleId IdType="pubmed">23314528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekri-Nechar K., Zamorano-Le&#xf3;n J.J., Reche C., Giner M., L&#xf3;pez-de-Andr&#xe9;s A., Jim&#xe9;nez-Garc&#xed;a R., L&#xf3;pez-Farr&#xe9; A.J., Mart&#xed;nez-Mart&#xed;nez C.H. Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa. Dis. Markers. 2022;2022:1118195. doi: 10.1155/2022/1118195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/1118195</ArticleId><ArticleId IdType="pmc">PMC9699787</ArticleId><ArticleId IdType="pubmed">36438904</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M.L., Chappard A., Singh B.P., Maclachlan C., Rodrigues M., Fedotova E.I., Berezhnov A.V., De S., Peddie C.J., Athauda D., et al. Pathological structural conversion of &#x3b1;-synuclein at the mitochondria induces neuronal toxicity. Nat. Neurosci. 2022;25:1134&#x2013;1148. doi: 10.1038/s41593-022-01140-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01140-3</ArticleId><ArticleId IdType="pmc">PMC9448679</ArticleId><ArticleId IdType="pubmed">36042314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. NeuroReport. 2000;11:211. doi: 10.1097/00001756-200001170-00041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200001170-00041</ArticleId><ArticleId IdType="pubmed">10683860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T., Buse J.B., Liebovitz D.M., Nicklas J.M., Puskarich M.A., Cohen K., Belani H.K., Anderson B.J., Huling J.D., Tignanelli C.J., et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): A multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect. Dis. 2023;23:1119&#x2013;1129. doi: 10.1016/S1473-3099(23)00299-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourget C., Adams K.V., Morshead C.M. Reduced microglia activation following metformin administration or microglia ablation is sufficient to prevent functional deficits in a mouse model of neonatal stroke. J. Neuroinflamm. 2022;19:146. doi: 10.1186/s12974-022-02487-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02487-x</ArticleId><ArticleId IdType="pmc">PMC9199194</ArticleId><ArticleId IdType="pubmed">35705953</ArticleId></ArticleIdList></Reference><Reference><Citation>DiBona V.L., Shah M.K., Krause K.J., Zhu W., Voglewede M.M., Smith D.M., Crockett D.P., Zhang H. Metformin reduces neuroinflammation and improves cognitive functions after traumatic brain injury. Neurosci. Res. 2021;172:99&#x2013;109. doi: 10.1016/j.neures.2021.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2021.05.007</ArticleId><ArticleId IdType="pmc">PMC8449802</ArticleId><ArticleId IdType="pubmed">34023358</ArticleId></ArticleIdList></Reference><Reference><Citation>Limphaibool N., Iwanowski P., Holstad M.J.V., Kobylarek D., Kozubski W. Infectious Etiologies of Parkinsonism: Pathomechanisms and Clinical Implications. Front. Neurol. 2019;10:652. doi: 10.3389/fneur.2019.00652.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00652</ArticleId><ArticleId IdType="pmc">PMC6593078</ArticleId><ArticleId IdType="pubmed">31275235</ArticleId></ArticleIdList></Reference><Reference><Citation>Almutairi M.M., Sivandzade F., Albekairi T.H., Alqahtani F., Cucullo L. Neuroinflammation and Its Impact on the Pathogenesis of COVID-19. Front. Med. 2021;8:745789. doi: 10.3389/fmed.2021.745789.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.745789</ArticleId><ArticleId IdType="pmc">PMC8652056</ArticleId><ArticleId IdType="pubmed">34901061</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R., Soung A., Sissoko C., Nordvig A., Canoll P., Mariani M., Jiang X., Bricker T., Goldman J., Rosoklija G., et al. COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis. Res. Sq. 2021 doi: 10.21203/rs.3.rs-1031824/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1031824/v1</ArticleId><ArticleId IdType="pmc">PMC8562542</ArticleId><ArticleId IdType="pubmed">34729556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz K.M., Nelson L.H. Microglia and Beyond: Innate Immune Cells As Regulators of Brain Development and Behavioral Function. Front. Immunol. 2018;9:698. doi: 10.3389/fimmu.2018.00698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00698</ArticleId><ArticleId IdType="pmc">PMC5908908</ArticleId><ArticleId IdType="pubmed">29706957</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C., Willscher E., Paschold L., Gottschick C., Klee B., Henkes S.-S., Bosurgi L., Dutzmann J., Sedding D., Frese T., et al. From online data collection to identification of disease mechanisms: The IL-1&#xdf;, IL-6 and TNF-&#x3b1; cytokine triad is associated with post-acute sequelae of COVID-19 in a digital research cohort. medRxiv. 2021</Citation></Reference><Reference><Citation>Patterson B.K., Guevara-Coto J., Yogendra R., Francisco E.B., Long E., Pise A., Rodrigues H., Parikh P., Mora J., Mora-Rodr&#xed;guez R.A. Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning. Front. Immunol. 2021;12:700782. doi: 10.3389/fimmu.2021.700782.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700782</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Menza M., DeFronzo Dobkin R., Marin H., Mark M.H., Gara M., Bienfait K., Dicke A., Kusnekov A. The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson&#x2019;s Disease. Psychosomatics. 2010;51:474&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987579</ArticleId><ArticleId IdType="pubmed">21051678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang P., Chong L., Li X., Liu Y., Liu P., Hou C., Li R. Correlation between Serum RANTES Levels and the Severity of Parkinson&#x2019;s Disease. Oxidative Med. Cell. Longev. 2014;2014:208408. doi: 10.1155/2014/208408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/208408</ArticleId><ArticleId IdType="pmc">PMC4283268</ArticleId><ArticleId IdType="pubmed">25587378</ArticleId></ArticleIdList></Reference><Reference><Citation>Festa B.P., Siddiqi F.H., Jimenez-Sanchez M., Won H., Rob M., Djajadikerta A., Stamatakou E., Rubinsztein D.C. Microglial-to-neuronal CCR5 signaling regulates autophagy in neurodegeneration. Neuron. 2023;111:2021&#x2013;2037.e12. doi: 10.1016/j.neuron.2023.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2023.04.006</ArticleId><ArticleId IdType="pubmed">37105172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., An K., Mao Z., Qu Y., Wang D., Li J., Min Z., Xue Z. CCL5 promotes LFA-1 expression in Th17 cells and induces LCK and ZAP70 activation in a mouse model of Parkinson&#x2019;s disease. Front. Aging Neurosci. 2023;15:1250685. doi: 10.3389/fnagi.2023.1250685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2023.1250685</ArticleId><ArticleId IdType="pmc">PMC10655117</ArticleId><ArticleId IdType="pubmed">38020765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae E.-J., Choi M., Kim J.T., Kim D.-K., Jung M.K., Kim C., Kim T.-K., Lee J.S., Jung B.C., Shin S.J., et al. TNF-&#x3b1; promotes &#x3b1;-synuclein propagation through stimulation of senescence-associated lysosomal exocytosis. Exp. Mol. Med. 2022;54:788&#x2013;800. doi: 10.1038/s12276-022-00789-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00789-x</ArticleId><ArticleId IdType="pmc">PMC9352737</ArticleId><ArticleId IdType="pubmed">35790884</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira J.C., Moreira T.C.L., De Ara&#xfa;jo A.L., Imamura M., Damiano R.F., Garcia M.L., Sawamura M.V., Pinna F.R., Guedes B.F., Gon&#xe7;alves F.A.R., et al. Clinical, sociodemographic and environmental factors impact post-COVID-19 syndrome. J. Glob. Health. 2022;12:05029. doi: 10.7189/jogh.12.05029.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.12.05029</ArticleId><ArticleId IdType="pmc">PMC9359428</ArticleId><ArticleId IdType="pubmed">35939273</ArticleId></ArticleIdList></Reference><Reference><Citation>Langston J.W. The MPTP Story. J. Park. Dis. 2017;7:S11&#x2013;S19. doi: 10.3233/JPD-179006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-179006</ArticleId><ArticleId IdType="pmc">PMC5345642</ArticleId><ArticleId IdType="pubmed">28282815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadasivan S., Sharp B., Schultz-Cherry S., Smeyne R.J. Synergistic effects of influenza and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can be eliminated by the use of influenza therapeutics: Experimental evidence for the multi-hit hypothesis. Npj Park. Dis. 2017;3:18. doi: 10.1038/s41531-017-0019-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-017-0019-z</ArticleId><ArticleId IdType="pmc">PMC5460228</ArticleId><ArticleId IdType="pubmed">28649618</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy H., Tandel D., Siddiqui A.H., Harshan K.H. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res. 2023;323:199010. doi: 10.1016/j.virusres.2022.199010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.199010</ArticleId><ArticleId IdType="pmc">PMC9676078</ArticleId><ArticleId IdType="pubmed">36417940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-L&#xf3;pez C., Cervantes-Luevano K., Aguirre-S&#xe1;nchez J.S., Flores-Caballero J.C., Alvarez-Delgado C., Bernaldez-Sarabia J., S&#xe1;nchez-Campos N., Lugo-S&#xe1;nchez L.A., Rodr&#xed;guez-V&#xe1;zquez I.C., Sander-Padilla J.G., et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial. Biomed. Pharmacother. 2022;152:113223. doi: 10.1016/j.biopha.2022.113223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113223</ArticleId><ArticleId IdType="pmc">PMC9159967</ArticleId><ArticleId IdType="pubmed">35709650</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., White K.M., O&#x2019;Meara M.J., Rezelj V.V., Guo J.Z., Swaney D.L., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459&#x2013;468. doi: 10.1038/s41586-020-2286-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller M.A., Sharma Y., Dupee Z., Nguyen D., Urue&#xf1;a J., Smolchek R., Loeb J.C., Machuca T.N., Lednicky J.A., Odde D.J., et al. Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. JCI Insight. 2021;6:e148003. doi: 10.1172/jci.insight.148003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.148003</ArticleId><ArticleId IdType="pmc">PMC8492301</ArticleId><ArticleId IdType="pubmed">34357881</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrzejewski S., Gravel S.-P., Pollak M., St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2014;2:12. doi: 10.1186/2049-3002-2-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2049-3002-2-12</ArticleId><ArticleId IdType="pmc">PMC4147388</ArticleId><ArticleId IdType="pubmed">25184038</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>